Ranjit Shahani, a respected figure in the pharmaceutical industry, passed away at the age of 74. He served as the Vice-Chairman and Managing Director of Novartis (India) and played a significant role during Novartis’ patent battle concerning its blood cancer drug Glivec in India. Despite the emotional intensity and high-profile nature of the seven-year legal dispute, Shahani maintained a composed demeanour, earning him admiration for his resilience and grace under pressure.
Reflecting on the Glivec case, Shahani humorously remarked on whether the drug or himself became the center of attention during the global scrutiny. Despite the disappointment of losing the battle for patent protection, he remained deeply involved in the process, handling interactions with professionalism and respect. Shahani’s willingness to engage and explain Novartis’ perspective without resorting to disrespect left a lasting impression on those who covered the landmark case.
Known for his accessibility and insightful conversations, Shahani’s commitment to fostering an innovative ecosystem in the pharmaceutical industry was evident. He navigated the delicate balance of representing both Indian interests and a multinational corporation, advocating for liberalizing policies and increased investment in healthcare while also urging Novartis to invest in India despite challenges.
Shahani’s advocacy extended to combating counterfeit medicines, a cause he passionately referred to as ‘the perfect murder’. He held various leadership positions, including President Emeritus of the Organisation of Pharmaceuticals Producers of India (OPPI) and Chairman of JB Chemicals & Pharmaceuticals.
As reported by businessline, Krishna Sarma, Managing Partner of Corporate Law Group, commended Shahani for his compelling presentation of the innovation case to government officials in India and the United States. Ranjit Shahani’s legacy as a respectful and influential voice in the pharmaceutical industry will be remembered fondly by those who had the privilege of interacting with him.
